Author

N. M. Barnes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Logan· 2 shared L. Bruce· 2 shared M. Mazzon· 2 shared A. S. Lavado· 1 shared A. Teodosio· 1 shared C. A. Brady· 1 shared C. Matas de las Heras· 1 shared C. Pallini· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Logan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A clinical stage LMW-DS drug inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia

A. Logan, M. Mazzon, L. Bruce, N. M. Barnes

This study evaluates the LMW-DS drug ILB(R) for inhibiting coronavirus infection and modulating cytokine release from microglia, showing it blocks ACE2:spike interaction and reduces pro-inflammatory cytokines.

bioRxiv · Sep 7, 2022 · PreprintImmunology

A clinical stage LMW-DS drug inhibits infection of human cells by Dengue, Zika and Yellow Fever viruses

A. Logan, M. Mazzon, L. Bruce, N. M. Barnes

This study evaluates the antiviral potential of the clinical-stage drug ILB(R) against Dengue, Zika, and Yellow Fever viruses in human cells.

bioRxiv · Aug 31, 2022 · PreprintImmunology

A cell-based, spike protein binding assay highlights differences in antibody neutralising capacity for SARS-CoV-2 variants

N. Harrison, L. Richardson, C. Pallini, I. Morano, E. Jinks, J. Cowley, H. Chan, H. Hill, C. Matas de las Heras, A. Teodosio, A. S. Lavado, T. R. Dafforn, D. K. Grammatopoulos, J. Gordon, C. A. Brady, , O. S. Qureshi

The paper develops a cell-based ACE2/spike protein binding assay to assess antibody neutralising capacity against SARS-CoV-2 variants and shows differential blocking activity of monoclonal antibodies.

bioRxiv · Jun 24, 2022 · PreprintCell Biology